Logo do repositório
 
Publicação

Serological evidence of SARS-CoV-2 infection in a hospital based cohort study of healthcare workers following the 2023 COVID-19 vaccination program

2024-09-24Documento de conferência Acesso aberto
Ver registo simples
dc.contributor.authorAlmeida Santos, João
dc.contributor.authorGaio, Vânia
dc.contributor.authorAmaral, Palmira
dc.contributor.authorHenriques, Camila
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorMachado, Ausenda
dc.date.accessioned2026-06-16T10:02:43Z
dc.date.available2026-06-16T10:02:43Z
dc.date.issued2024-09-24
dc.description.abstractObjective: Healthcare workers (HCWs) are a high-risk population to acquire SARS-CoV-2 infection and becoming a focus of transmission. It is therefore important to monitor these professionals, especially due to asymptomatic infections. The objective the study was to assess SARS-CoV-2 infection rates in healthcare professionals at a central Portuguese hospital using serological tests, three and six months after the 2023 COVID-19 booster vaccination program. Methods: A prospective cohort study was established through serological follow-up in a cohort of healthcare professionals from a central Portuguese hospital, with three rounds of tests: pre-COVID-19 vaccination (September/October 2023), 3 months (January/February 2024) and 6 months (April/May 2024) post-vaccination. IgG antibodies specific to the SARS-CoV-2 nucleocapsid protein (anti-N) were measured. Data was analyzed trough descriptive statistics (frequency, mean, percentages) and infection rates at each testing moment (0, 3 and 6 months). Results: At baseline, all participants (n=177, median age: 47years, 77,4% females) had the complete primary COVID-19 vaccination, with 78% having received 2 additional booster doses prior to 2023 vaccination program. Pre vaccination, 48,6% (86/177) of HCWs had detectable anti-N IgG antibodies, of which 24,4% (21/86) self-reported having had a SARS-Cov-2 infection in 2022/2023. After 3 months, 17,7% (n=11/62) had detectable anti-N IgG antibodies although being negative in the pre-vaccination testing. After 6 months, 4,3% (n=2/47) had detectable anti-N IgG antibodies but were negative in the previous two rounds. Conclusions: During the study period, several cases of SAR-CoV-2 infection (n=13) were identified serologically among the HCW monitored, without concomitant signs and symptoms that would allow the identification of a potential infection. These results support that monitoring the infection among HCW (regardless of history of symptoms) can provide valuable information for assessing the level of exposure among hospital personnel and identifying high-risk departments. This information could allow early intervention by, for example, reminding and reinforcing the importance of personal protection standards for HCWs.pt_PT
dc.description.sponsorshipThis study was funded by European Centre for Disease Prevention and Control through “Vaccine Effectiveness, Burden and Impact Studies” (VEBIS) Lot 2 “Assessment of COVID-19 and influenza vaccine effectiveness among healthcare workers” framework contract ECDC/2021/017.
dc.description.versionN/Apt_PT
dc.identifier.urihttp://hdl.handle.net/10400.18/11330
dc.language.isoengpt_PT
dc.peerreviewedn/a
dc.rights.uriN/A
dc.subjectSARS-CoV-2pt_PT
dc.subjectCOVID-19
dc.subjectSerological Statuspt_PT
dc.subjectVaccinespt_PT
dc.subjectVEBIS
dc.subjectPublic Healthpt_PT
dc.subjectEstados de Saúde e de Doençapt_PT
dc.subjectInfecções Respiratórias
dc.titleSerological evidence of SARS-CoV-2 infection in a hospital based cohort study of healthcare workers following the 2023 COVID-19 vaccination programeng
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferenceDate2024-09-24
oaire.citation.conferencePlaceÉvora, Portugal
oaire.citation.title5th CHRC Annual Summit, 23,24 September 2024
oaire.versionhttp://purl.org/coar/version/c_b1a7d7d4d402bcce
person.familyNameAlmeida Santos
person.familyNameGaio
person.familyNameValadas Henriques
person.familyNameGuiomar
person.familyNameMachado
person.givenNameJoão
person.givenNameVânia
person.givenNameCamila
person.givenNameRaquel
person.givenNameAusenda
person.identifier1709999
person.identifier.ciencia-id9012-DD7F-745F
person.identifier.ciencia-idA71A-17AF-30C7
person.identifier.ciencia-id851F-4E5E-D0AD
person.identifier.ciencia-idAE10-5FAB-7439
person.identifier.ciencia-id1217-6076-5D88
person.identifier.orcid0000-0002-8564-1098
person.identifier.orcid0000-0001-7626-4991
person.identifier.orcid0000-0002-3654-4929
person.identifier.orcid0000-0002-4563-6315
person.identifier.orcid0000-0002-1849-1499
person.identifier.scopus-author-id57210569889
person.identifier.scopus-author-id56080468200
rcaap.rightsclosedAccesspt_PT
rcaap.typeotherpt_PT
relation.isAuthorOfPublicationd1a7b2d4-9a19-4a3a-9389-fd049d8db5ca
relation.isAuthorOfPublication59791814-187c-4b34-b3a2-6ad67a213814
relation.isAuthorOfPublication6fe03523-acfc-4a28-ba2d-ab0d9b911d1e
relation.isAuthorOfPublication9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublication.latestForDiscovery544ad266-0c22-4a50-9ebc-86acc08d6666

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
CHRC_NC_2024_vf.pdf
Tamanho:
1.33 MB
Formato:
Adobe Portable Document Format
Descrição:
Poster
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DEP - Posters/abstracts em congressos nacionais
DDI - Posters/abstracts em congressos nacionais